Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab With or Without Cryoablation in Metastatic Renal Cell Carcinoma
NCT02626130Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2016
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tremelimumab in renal cell carcinoma (RCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 2 weeks and Incidence of extreme toxicities up to 2 weeks. Started Mar 2016; status: completed.
02
Drugs
tremelimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02626130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626130.